Further studies addressing the effects of targeting TGF-β signalling by galunisertib in macrophages and Treg cells, and the consequent potential modulation of the immunosuppressive tumour microenvironment and chemoresistance in pancreatic cancer are warranted. This evidence concerns the gene TGFB1 and familial pancreatic carcinoma.